Chardan Capital reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research note published on Monday, Benzinga reports. They currently have a $14.00 price objective on the stock.
Coya Therapeutics Stock Performance
NASDAQ COYA traded down $0.22 during trading hours on Monday, reaching $8.38. 30,334 shares of the company's stock were exchanged, compared to its average volume of 85,365. The company has a market capitalization of $122.35 million, a price-to-earnings ratio of -10.74 and a beta of 0.80. The company's 50-day moving average is $9.20 and its two-hundred day moving average is $7.18. Coya Therapeutics has a one year low of $3.21 and a one year high of $10.69.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its earnings results on Tuesday, March 19th. The company reported $0.15 earnings per share for the quarter. The company had revenue of $6.00 million during the quarter.
Hedge Funds Weigh In On Coya Therapeutics
Several hedge funds have recently made changes to their positions in COYA. Greenlight Capital Inc. boosted its holdings in Coya Therapeutics by 172.2% during the fourth quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company's stock worth $9,441,000 after purchasing an additional 805,959 shares during the last quarter. AIGH Capital Management LLC boosted its stake in shares of Coya Therapeutics by 92.6% during the 4th quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company's stock worth $7,381,000 after buying an additional 496,183 shares during the last quarter. Finally, CM Management LLC boosted its stake in shares of Coya Therapeutics by 66.7% during the 3rd quarter. CM Management LLC now owns 100,000 shares of the company's stock worth $384,000 after buying an additional 40,000 shares during the last quarter. 39.75% of the stock is owned by institutional investors.
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Further Reading
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
